Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-20), SHL Telemedicine's 9-Day RSI is 53.12.
The industry rank for SHL Telemedicine's 9-Day RSI or its related term are showing as below:
XSWX:SHLTN's 9-Day RSI is ranked worse than 62.21% of 696
companies
in the Healthcare Providers & Services industry
Industry Median: 47.785
vs XSWX:SHLTN: 53.12
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
SHL Telemedicine 9-Day RSI Related Terms
XSWX:SHLTN vs VEEV, BTSG, TEM: 9-Day RSI Comparison
For the Health Information Services subindustry, SHL Telemedicine's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHL Telemedicine (XSWX:SHLTN) has a 9-Day RSI of 53.12 as of Jul. 20, 2026. According to the industry distribution chart, SHL Telemedicine ranks #433 out of 696 companies in the Healthcare Providers & Services industry, placing it in the top 62.2%.
Is SHL Telemedicine's 9-Day RSI too high?
SHL Telemedicine's current 9-Day RSI is 53.12. The Healthcare Providers & Services industry median 9-Day RSI is 47.79. SHL Telemedicine's value of 53.12 is 11.2% above this industry median. Based on the distribution chart, SHL Telemedicine ranks #433 out of 696 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, SHL Telemedicine has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's 9-Day RSI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #433 out of 696 companies for 9-Day RSI. This places SHL Telemedicine in the lower half of its industry. The industry median 9-Day RSI is 47.79. SHL Telemedicine's value of 53.12 is 11.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 47.79, based on 696 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SHL Telemedicine's current 9-Day RSI of 53.12 is 11.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 47.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SHL Telemedicine's current 9-Day RSI is 53.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
Based on GuruFocus' analysis, SHL Telemedicine (XSWX:SHLTN) is currently considered Possible Value Trap. The stock's GF Value™ is CHF2.62, compared to a current price of CHF1.04 — trading 60.5% below its estimated fair value. The current 9-Day RSI is 53.12 and 11.2% above the Healthcare Providers & Services industry median of 47.79. SHL Telemedicine's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For SHL Telemedicine (XSWX:SHLTN), the current 9-Day RSI is 53.12 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (XSWX:SHLTN) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of CHF1.04 is trading 60.5% below its estimated GF Value™ of CHF2.62.
GuruFocus considers SHL Telemedicine to be Possible Value Trap.
Key valuation signals for XSWX:SHLTN:
9-Day RSI: 53.12
GF Value™: CHF2.62 vs. price of CHF1.04 (60.5% below fair value)
Industry Position: 11.2% above the Healthcare Providers & Services median (#433 of 696)
No single metric tells the full story. See the XSWX:SHLTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
52GF Score
Get the complete analysis for XSWX:SHLTN
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SHLTN has been successfully added to your 
